276 related articles for article (PubMed ID: 26228656)
1. Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner.
Sharma SK; Chorell E; Steneberg P; Vernersson-Lindahl E; Edlund H; Wittung-Stafshede P
Sci Rep; 2015 Jul; 5():12531. PubMed ID: 26228656
[TBL] [Abstract][Full Text] [Related]
2. Insulin-degrading enzyme is activated by the C-terminus of α-synuclein.
Sharma SK; Chorell E; Wittung-Stafshede P
Biochem Biophys Res Commun; 2015 Oct; 466(2):192-5. PubMed ID: 26343304
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the Activity of the Insulin-Degrading Enzyme by Aβ Peptides.
Kemeh MM; Lazo ND
ACS Chem Neurosci; 2023 Aug; 14(16):2935-2943. PubMed ID: 37498802
[TBL] [Abstract][Full Text] [Related]
4. Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases.
Sousa L; Guarda M; Meneses MJ; Macedo MP; Vicente Miranda H
J Pathol; 2021 Dec; 255(4):346-361. PubMed ID: 34396529
[TBL] [Abstract][Full Text] [Related]
5. Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases.
Yagi H; Kusaka E; Hongo K; Mizobata T; Kawata Y
J Biol Chem; 2005 Nov; 280(46):38609-16. PubMed ID: 16162499
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.
Guo Q; Manolopoulou M; Bian Y; Schilling AB; Tang WJ
J Mol Biol; 2010 Jan; 395(2):430-43. PubMed ID: 19896952
[TBL] [Abstract][Full Text] [Related]
7. Isolation of short peptide fragments from alpha-synuclein fibril core identifies a residue important for fibril nucleation: a possible implication for diagnostic applications.
Yagi H; Takeuchi H; Ogawa S; Ito N; Sakane I; Hongo K; Mizobata T; Goto Y; Kawata Y
Biochim Biophys Acta; 2010 Oct; 1804(10):2077-87. PubMed ID: 20637318
[TBL] [Abstract][Full Text] [Related]
8. Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme.
Zhang Z; Liang WG; Bailey LJ; Tan YZ; Wei H; Wang A; Farcasanu M; Woods VA; McCord LA; Lee D; Shang W; Deprez-Poulain R; Deprez B; Liu DR; Koide A; Koide S; Kossiakoff AA; Li S; Carragher B; Potter CS; Tang WJ
Elife; 2018 Mar; 7():. PubMed ID: 29596046
[TBL] [Abstract][Full Text] [Related]
9. Modulating α-synuclein fibril formation using DNA tetrahedron nanostructures.
Yoo WK; Ryu BH; Kim KR; Wang Y; Le LTHL; Lee JH; Kim KK; Toth G; Ahn DR; Doohun Kim T
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):73-81. PubMed ID: 30278239
[TBL] [Abstract][Full Text] [Related]
10. The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation.
Lorenzen N; Nielsen SB; Buell AK; Kaspersen JD; Arosio P; Vad BS; Paslawski W; Christiansen G; Valnickova-Hansen Z; Andreasen M; Enghild JJ; Pedersen JS; Dobson CM; Knowles TP; Otzen DE
J Am Chem Soc; 2014 Mar; 136(10):3859-68. PubMed ID: 24527756
[TBL] [Abstract][Full Text] [Related]
11. Contact between the β1 and β2 Segments of α-Synuclein that Inhibits Amyloid Formation.
Shaykhalishahi H; Gauhar A; Wördehoff MM; Grüning CS; Klein AN; Bannach O; Stoldt M; Willbold D; Härd T; Hoyer W
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8837-40. PubMed ID: 26119103
[TBL] [Abstract][Full Text] [Related]
12. Investigation on the Molecular Interactions Stabilizing the Structure of α-synuclein Fibril: An In silico Study.
Sanjeev A; Mattaparthi VSK
Cent Nerv Syst Agents Med Chem; 2017; 17(3):209-218. PubMed ID: 28460628
[TBL] [Abstract][Full Text] [Related]
13. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
Shen Y; Joachimiak A; Rosner MR; Tang WJ
Nature; 2006 Oct; 443(7113):870-4. PubMed ID: 17051221
[TBL] [Abstract][Full Text] [Related]
14. Abundant fish protein inhibits α-synuclein amyloid formation.
Werner T; Kumar R; Horvath I; Scheers N; Wittung-Stafshede P
Sci Rep; 2018 Apr; 8(1):5465. PubMed ID: 29615738
[TBL] [Abstract][Full Text] [Related]
15. Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates.
de Tullio MB; Castelletto V; Hamley IW; Martino Adami PV; Morelli L; Castaño EM
PLoS One; 2013; 8(4):e59113. PubMed ID: 23593132
[TBL] [Abstract][Full Text] [Related]
16. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein.
Kobayashi M; Kim J; Kobayashi N; Han S; Nakamura C; Ikebukuro K; Sode K
Biochem Biophys Res Commun; 2006 Oct; 349(3):1139-44. PubMed ID: 16962995
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effects of biomimetically designed peptides on α-synuclein aggregation.
Rezaeian N; Shirvanizadeh N; Mohammadi S; Nikkhah M; Arab SS
Arch Biochem Biophys; 2017 Nov; 634():96-106. PubMed ID: 28965745
[TBL] [Abstract][Full Text] [Related]
18. S100A9 Alters the Pathway of Alpha-Synuclein Amyloid Aggregation.
Toleikis Z; Ziaunys M; Baranauskiene L; Petrauskas V; Jaudzems K; Smirnovas V
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360737
[TBL] [Abstract][Full Text] [Related]
19. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
[TBL] [Abstract][Full Text] [Related]
20. Gallic acid interacts with α-synuclein to prevent the structural collapse necessary for its aggregation.
Liu Y; Carver JA; Calabrese AN; Pukala TL
Biochim Biophys Acta; 2014 Sep; 1844(9):1481-5. PubMed ID: 24769497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
